Drugs / [13C]Pantoprazole
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00668902 | Mar 2007 → Dec 2008 | — | Indiana University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [13C]Pantoprazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00668902 ↗ |
| Modality | Small molecule | “Pantoprazole, 5-(difluoromethoxy)-2-\[\[(3,4-dimethoxy-2-pyridyl)-methyl\]sulfinyl\]-1H -benzimidazole, is a substituted benzimidazole sulfoxide” NCT00668902 ↗ |
| Route | Intravenous | “Pantoprazole is approved as an oral and intravenous drug by the Food and Drug Administration (FDA).” NCT00668902 ↗ |
| Route | Oral | “Pantoprazole is approved as an oral and intravenous drug by the Food and Drug Administration (FDA).” NCT00668902 ↗ |